- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 183293-82-5] Gemcabene
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-109567 |
| Brand: | MCE |
| CAS: | 183293-82-5 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 302.41 |
| Molecular Formula | C16H30O5 |
| SMILES | O=C(O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O |
Summary
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity [1] [2] [3] .
In Vitro
Gemcabene calcium (PD-72953 calcium) significantly downregulates hepatic mRNA markers of inflammation (TNF-α, MCP-1, MIP-1β, CCR5, CCR2, NF-κB), lipogenesis and lipid modulation (ApoC-III, ACC1, ADH-4, Sulf-2), and fibrosis (TIMP-1 and MMP-2) [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02944383 | NeuroBo Pharmaceuticals Inc. |
Severe Hypertriglyceridemia|Mixed Dyslipidaemia
|
December 2016 | Phase 2 |
| NCT02591836 | NeuroBo Pharmaceuticals Inc. |
Hypercholesterolemia
|
January 2003 | Phase 2 |
| NCT02587364 | NeuroBo Pharmaceuticals Inc. |
Hypercholesterolemia
|
April 1999 | Phase 1 |
| NCT02585869 | NeuroBo Pharmaceuticals Inc. |
Hypercholesterolemia|Hypertriglyceridemia
|
December 1999 | Phase 2 |
| NCT02587416 | NeuroBo Pharmaceuticals Inc. |
Hypercholesteremia
|
November 2002 | Phase 1 |
| NCT02587390 | NeuroBo Pharmaceuticals Inc. |
Hypercholesterolemia
|
May 2000 | Phase 1 |
| NCT02722408 | NeuroBo Pharmaceuticals Inc. |
Hypercholesteremia
|
June 2016 | Phase 2 |
| NCT02571257 | NeuroBo Pharmaceuticals Inc. |
Hypercholesterolemia
|
August 2000 | Phase 2 |
| NCT03508687 | Elif Oral|University of Michigan |
Familial Partial Lipodystrophy|Hypertriglyceridemia|Fatty Liver|NASH - Nonalcoholic Steatohepatitis
|
March 13, 2018 | Phase 1|Phase 2 |
| NCT02586168 | NeuroBo Pharmaceuticals Inc. |
Insulin Sensitivity
|
July 2001 | Phase 2 |
| NCT03436420 | Emory University|Gemphire Therapeutics |
Non-Alcoholic Fatty Liver Disease
|
March 29, 2018 | Phase 2 |
| NCT02634151 | NeuroBo Pharmaceuticals Inc. |
Hypercholesteremia
|
November 2016 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 330.68 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.3068 mL | 16.5338 mL | 33.0677 mL |
| 5 mM | 0.6614 mL | 3.3068 mL | 6.6135 mL |
| 10 mM | 0.3307 mL | 1.6534 mL | 3.3068 mL |
References
- [1] Mandema JW, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7(3):E513-22.
- [2] Srivastava RAK, et al. Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. Front Pharmacol. 2018 May 11;9:471.
- [3] Oniciu DC, et al. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. PLoS One. 2018 May 30;13(5):e0194568.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.